NodThera Email Format
Biotechnology ResearchPennsylvania, United States11-50 Employees
NodThera is developing a new class of potent and highly selective NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic inflammation. Weβre building a dynamic team of people across our offices in Cambridge, UK and Boston, MA; all united by our shared ambition, enthusiasm, and creativity.